Literature DB >> 1314107

Histoplasmosis in Indianapolis.

L J Wheat1.   

Abstract

Recurrent outbreaks of histoplasmosis in Indianapolis since 1978 have expanded our understanding of histoplasmosis. Histoplasmosis has emerged as the leading opportunistic infection in patients with AIDS from Indianapolis. Clinical manifestations of histoplasmosis are influenced by host factors. Underlying lung disease predisposes to chronic pulmonary histoplasmosis, and immunosuppressive medications or disorders predispose to dissemination. Inflammatory manifestations, including arthritis, erythema nodosum, and pericarditis, commonly occur with acute histoplasmosis. Diagnosis of histoplasmosis requires understanding of the accuracy and limitations of cultural and serological methods. More recently, radioimmunoassay for polysaccharide antigen has offered a new diagnostic approach. Amphotericin B remains the gold standard for treatment and is highly effective, even in immunocompromised individuals. Itraconazole shows promise as an alternative to amphotericin B for treatment of less severely ill patients. The role of fluconazole in therapy remains unknown until ongoing clinical trials are completed. Histoplasmosis cannot be cured in individuals with AIDS and in a small proportion of other individuals with other underlying immunosuppressive conditions. In such cases, long-term maintenance treatment is required to prevent relapse. Antigen detection has proven useful for following progress during treatment and for identifying relapse.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1314107     DOI: 10.1093/clinids/14.supplement_1.s91

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  16 in total

Review 1.  Transmission of tropical and geographically restricted infections during solid-organ transplantation.

Authors:  P Martín-Dávila; J Fortún; R López-Vélez; F Norman; M Montes de Oca; P Zamarrón; M I González; A Moreno; T Pumarola; G Garrido; A Candela; S Moreno
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

2.  Pulmonary histoplasmosis as an example of imported mycoses in Japan.

Authors:  Akira Shimamoto; Motoshi Takao; Shin Shomura; Tomohito Tarukawa; Hideto Shimpo
Journal:  Gen Thorac Cardiovasc Surg       Date:  2007-08

Review 3.  Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis.

Authors:  K N Sorensen; K V Clemons; D A Stevens
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

Review 4.  Diagnosis of invasive mycoses in severely immunosuppressed patients.

Authors:  R Rüchel
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

Review 5.  Tropical respiratory medicine. 3. Histoplasmosis and pulmonary involvement in the tropics.

Authors:  S Houston
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

Review 6.  Diagnosis of histoplasmosis: current status and perspectives.

Authors:  María Agustina Toscanini; Alejandro David Nusblat; María Luján Cuestas
Journal:  Appl Microbiol Biotechnol       Date:  2021-02-15       Impact factor: 4.813

7.  Pulmonary Histoplasmosis.

Authors:  Carol A. Kauffman
Journal:  Curr Infect Dis Rep       Date:  2001-06       Impact factor: 3.725

Review 8.  Histoplasma mechanisms of pathogenesis--one portfolio doesn't fit all.

Authors:  Jessica A Edwards; Chad A Rappleye
Journal:  FEMS Microbiol Lett       Date:  2011-08-09       Impact factor: 2.742

9.  PCR assay for identification of histoplasma capsulatum based on the nucleotide sequence of the M antigen.

Authors:  Herbert Leonel de Matos Guedes; Allan Jefferson Guimarães; Mauro de Medeiros Muniz; Claudia Vera Pizzini; Andrew John Hamilton; José Mauro Peralta; George S Deepe; Rosely M Zancopé-Oliveira
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

10.  Factors associated with Paracoccidiodes brasiliensis infection among permanent residents of three endemic areas in Colombia.

Authors:  D Cadavid; A Restrepo
Journal:  Epidemiol Infect       Date:  1993-08       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.